Doravirine Use in Treatment-Experienced HIV-Positive Patients

Abstract

Get full access to this article

View all access options for this article.

References

Blevins

Hester

Chastain

Cluck

DB.

Doravirine: a return of the NNRTI class?

Ann Pharmacother. 2020;54:64-74. doi:10.1177/1060028019869641

Pifeltro. Package insert. Merck & Co Inc; 2019.

Johnson

Kumar

Molina

, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81:463-472. doi:10.1097/QAI.0000000000002056

Wong

Goldstein

Mallolas

, et al. Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) in treatment-naive adults with HIV-1 and transmitted nonnucleoside reverse transcriptase inhibitor resistance mutations. J Acquir Immune Defic Syndr. 2019;82:e47-e49. doi:10.1097/QAI.0000000000002153

Sterrantino

Borghi

Callegaro

, et al. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019;53:515-519. doi:10.1016/j.ijantimicag.2019.02.007

Lai

Feng

Falgueyret

, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58:1652-1663. doi:10.1128/AAC.02403-13

Soulie

Santoro

Storto

, et al. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. J Antimicrob Chemother. 2020;75:1026-1030. doi:10.1093/jac/dkz553